These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 12400405)
21. Variant Creutzfeldt-Jakob disease and prions in the blood supply. Rohwer RG; Drohan W Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166 [No Abstract] [Full Text] [Related]
22. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Turner ML; Ludlam CA Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452 [TBL] [Abstract][Full Text] [Related]
23. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease. Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827 [TBL] [Abstract][Full Text] [Related]
24. Universal leucodepletion to reduce the risk of transmission of new-variant Creutzfeldt-Jakob disease. Sivakumaran M Br J Haematol; 2000 Jul; 110(1):234. PubMed ID: 10991551 [No Abstract] [Full Text] [Related]
25. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902 [TBL] [Abstract][Full Text] [Related]
28. American fresh frozen plasma for neonates and children. Norfolk DR; Glaser A; Kinsey S Arch Dis Child; 2005 Jan; 90(1):89-91. PubMed ID: 15613525 [TBL] [Abstract][Full Text] [Related]
29. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Ludlam CA; Turner ML Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015 [TBL] [Abstract][Full Text] [Related]
30. US blood ban underlines CJD fears. Wadman M Nature; 2001 Jul; 412(6842):7. PubMed ID: 11452271 [No Abstract] [Full Text] [Related]
31. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Brown P Haemophilia; 2007 Dec; 13 Suppl 5():33-40. PubMed ID: 18078395 [TBL] [Abstract][Full Text] [Related]
32. Of mad cows and bolted horses: the economics of blood safety. Murphy WG Transfusion; 2012 Nov; 52(11):2278-81. PubMed ID: 23140426 [No Abstract] [Full Text] [Related]
33. [The impact of the implementation of staying in the United Kingdom for six months or more as donor exclusion criteria on the donor base of the Basque Country]. Pérez Vaquero MA; Basaldua MA; Ibarra A; Renovales A; Larrea A; Vesga MA Med Clin (Barc); 2001 Mar; 116(11):413-5. PubMed ID: 11333688 [TBL] [Abstract][Full Text] [Related]
34. New variant Creutzfeldt-Jakob disease: a controversial but potential blood transfusion risk. Basu A Nepal Med Coll J; 2003 Jun; 5(1):51-2. PubMed ID: 16583978 [No Abstract] [Full Text] [Related]
35. Leucocyte depletion of the blood supply - how will patients benefit? Williamson LM Br J Haematol; 2000 Aug; 110(2):256-72. PubMed ID: 10971381 [No Abstract] [Full Text] [Related]
36. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Dorsey K; Zou S; Schonberger LB; Sullivan M; Kessler D; Notari E; Fang CT; Dodd RY Transfusion; 2009 May; 49(5):977-84. PubMed ID: 19170987 [TBL] [Abstract][Full Text] [Related]